Inhibrx, Inc.
LA JOLLA, CA · Founded 2017 · CIK 0001739614 · Biotech · Acquired
Multi-specific therapeutic antibodies targeting Staphylococcus aureus toxins and cell surface proteins using engineered heavy chain-only variable domains (VHHs) linked to modified Fc domains
inhibrx.com →- Grants
- $448K
- 2 awards
- Sector median: 1
- Raised
- $669M
- 5 Form D · Aug 2023
- 38 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 16 granted · 24 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of multispecific antibodies for the treatment of Pseudomonas aeruginosa infection | $223,854 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Multispecific Antibodies for the treatment of Methicillin Resistant Staphylococcus aureus MRSA infection | $224,402 | |
| Private capital raised | Form D · SEC | $410,000,006 | |
| Private capital raised | Form D · SEC | $3,550,000 | |
| Private capital raised | Form D · SEC | $40,000,000 | |
| Private capital raised | Form D · SEC | $15,000,000 | |
| Private capital raised | Form D · SEC | $200,000,633 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1123 | Walden Biosciences | — | — |
| 1124 | Kriya Therapeutics | — | $769M |
| 1125 | VERSATOPE THERAPEUTICS, INC. | — | — |
| 1126 | Inhibrx, Inc. | — | $669M |
| 1127 | Odyssey Therapeutics | — | $571M |
| 1128 | Moderna | — | $556M |
| 1129 | Mariana Oncology | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Kelly DeckExecutive Officer
- Brendan EckelmanDirector · Executive Officer
- Margery FischbeinDirector
- Doug ForsythDirector
- Douglas ForsythDirector
- Jon KayyemDirector
- Mark LappeDirector · Executive Officer
- Judith LiDirector
- Kimberly ManhardDirector
- Kristiina VuoriDirector
Patents
- CD33 Targeted Immunotherapiesapplication
- CLL-1 Targeted Immunotherapiesapplication
- OX40-Binding Polypeptides and Uses Thereofapplication
- Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Usesapplication
- FcRn-Binding Polypeptides and Uses Thereofapplication
- DLL3 Single Domain Antibodies And Therapeutic Compositions Thereofapplication
- DR5 Agonist and IAP Antagonist Combination Therapyapplication
- Albumin-Binding Polypeptides and Uses Thereofapplication
- Uses Of PDL1-BINDING Proteinsapplication
- Non-immunogenic Single Domain Antibodiesapplication
- DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapyapplication
- OX40-Binding Polypeptides and Uses Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.